Wegovy is administered as a once-weekly subcutaneous injection, typically starting at a low dose of 0.25mg and gradually increasing over 16 weeks to the maintenance dose of 2.4mg, with each dose level maintained for 4 weeks
Baar et al., Cell 2017: targeted apoptosis of senescent cells (PubMed) Baar et al
ROS acts as upstream signals for NLRP3 inflammasome activation by upregulating the expression of key components, including NLRP3, pro-CASP1, and pro-IL1B [141]
The FDA provides examples of acceptable documentation for the significant difference determination, including: No Dye X, patient allergy (if the comparable drug contains the dye) Liquid form, patient cant swallow tablet (if the comparable drug is a tablet) 6 mg, patient needs higher dose (if the comparable drug is only available in 5 mg dose) For providers offering weight management services, remember that the prescription documentation needs to establish why combining the GLP-1 with an additive results in a significant difference compared to administering them separately
Individuals with a history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 should not use Liraglutide
Evaluation : Dr